Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND)

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2022 Jul 22

PMID 35867211

Authors

Dennis L Kolson

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Reducing the risk of HIV-associated neurocognitive disorders (HAND) is an elusive treatment goal for people living with HIV. Combination antiretroviral therapy (cART) has reduced the prevalence of HIV-associated dementia, but milder, disabling HAND is an unmet challenge. As newer cART regimens that more consistently suppress central nervous system (CNS) HIV replication are developed, the testing of adjunctive neuroprotective therapies must accelerate.

Recent Findings: Successes in modifying cART regimens for CNS efficacy (penetrance, chemokine receptor targeting) and delivery (nanoformulations) in pilot studies suggest that improving cART neuroprotection and reducing HAND risk is achievable. Additionally, drugs currently used in neuroinflammatory, neuropsychiatric, and metabolic disorders show promise as adjuncts to cART, likely by broadly targeting neuroinflammation, oxidative stress, aerobic metabolism, and/or neurotransmitter metabolism. Adjunctive cognitive brain therapy and aerobic exercise may provide additional efficacy. Adjunctive neuroprotective therapies, including available FDA-approved drugs, cognitive therapy, and aerobic exercise combined with improved cART offer plausible strategies for optimizing the prevention and treatment of HAND.

Citing Articles

Antiretroviral drug therapy does not reduce neuroinflammation in an HIV-1 infection brain organoid model.

Martinez-Meza S, Premeaux T, Cirigliano S, Friday C, Michael S, Mediouni S J Neuroinflammation. 2025; 22(1):66.

PMID: 40045391 PMC: 11881274. DOI: 10.1186/s12974-025-03375-w.

Bridging brain and blood: a prospective view on neuroimaging-exosome correlations in HIV-associated neurocognitive disorders.

Luo H, Chen J, Liu J, Wang W, Hou C, Jiang X Front Neurol. 2025; 15():1479272.

PMID: 39839878 PMC: 11745957. DOI: 10.3389/fneur.2024.1479272.

Ten Years of ® : Decade in Review.

Dalmau J, Dalakas M, Kolson D, Probstel A, Paul F, Zamvil S Neurol Neuroimmunol Neuroinflamm. 2024; 12(1):e200363.

PMID: 39724529 PMC: 11676263. DOI: 10.1212/NXI.0000000000200363.

Infectious Disease as a Modifiable Risk Factor for Dementia: A Narrative Review.

Farrer T, Moore J, Chase M, Gale S, Hedges D Pathogens. 2024; 13(11).

PMID: 39599527 PMC: 11597442. DOI: 10.3390/pathogens13110974.

ROS Chronicles in HIV Infection: Genesis of Oxidative Stress, Associated Pathologies, and Therapeutic Strategies.

Harshithkumar R, Shah P, Jadaun P, Mukherjee A Curr Issues Mol Biol. 2024; 46(8):8852-8873.

PMID: 39194740 PMC: 11352872. DOI: 10.3390/cimb46080523.

References

Everall I, Bell C, Mallory M, Langford D, Adame A, Rockestein E . Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci. 2002; 21(3):493-501. DOI: 10.1006/mcne.2002.1196. View

Gill A, Kolson D . Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol. 2013; 33(4):307-59. PMC: 3753696. DOI: 10.1615/critrevimmunol.2013007247. View

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Eshun-Wilson I, Siegfried N, Akena D, Stein D, Obuku E, Joska J . Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018; 1:CD008525. PMC: 6491182. DOI: 10.1002/14651858.CD008525.pub3. View

Chan P, Kerr S, Kroon E, Colby D, Sacdalan C, Hellmuth J . Cognitive trajectories after treatment in acute HIV infection. AIDS. 2021; 35(6):883-888. DOI: 10.1097/QAD.0000000000002831. View

Tong N, Sanchez J, Maggirwar S, Ramirez S, Guo H, Dewhurst S . Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci. 2001; 13(10):1913-22. DOI: 10.1046/j.0953-816x.2001.01572.x. View

Stefanou M, Palaiodimou L, Katsanos A, Milionis H, Kosmidou M, Lambadiari V . The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2022; 58:103395. DOI: 10.1016/j.msard.2021.103395. View

Fuchs J, Oelke N, Imhof M, Ochsendorf F, Schofer H, Oromek G . Multiparameter analysis of clastogenic factors, pro-oxidant cytokines, and inflammatory markers in HIV-1-infected patients with asymptomatic disease, opportunistic infections, and malignancies. Mol Med. 1998; 4(5):333-43. PMC: 2230378. View

Driscoll K . TNFalpha and MIP-2: role in particle-induced inflammation and regulation by oxidative stress. Toxicol Lett. 2000; 112-113:177-83. DOI: 10.1016/s0378-4274(99)00282-9. View

10.

Palamara A, Perno C, Aquaro S, Bue M, Dini L, Garaci E . Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. AIDS Res Hum Retroviruses. 1996; 12(16):1537-41. DOI: 10.1089/aid.1996.12.1537. View

11.

Ambrosius B, Gold R, Chan A, Faissner S . Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. Neurol Neuroimmunol Neuroinflamm. 2019; 6(3):e551. PMC: 6501636. DOI: 10.1212/NXI.0000000000000551. View

12.

Marra C, Zhao Y, Clifford D, Letendre S, Evans S, Henry K . Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009; 23(11):1359-66. PMC: 2706549. DOI: 10.1097/QAD.0b013e32832c4152. View

13.

Valcour V, Shiramizu B . HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion. 2005; 4(2-3):119-29. DOI: 10.1016/j.mito.2004.05.009. View

14.

Suresh D, Annam V, Pratibha K, Prasad B . Total antioxidant capacity--a novel early bio-chemical marker of oxidative stress in HIV infected individuals. J Biomed Sci. 2009; 16:61. PMC: 2714592. DOI: 10.1186/1423-0127-16-61. View

15.

Gill A, Garza R, Ambegaokar S, Gelman B, Kolson D . Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection. J Neuroinflammation. 2018; 15(1):70. PMC: 5838989. DOI: 10.1186/s12974-018-1102-z. View

16.

Letendre S, Marquie-Beck J, Ellis R, Woods S, Best B, Clifford D . The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol. 2007; 2(1):120-7. DOI: 10.1007/s11481-006-9054-y. View

17.

Schifitto G, Zhong J, Gill D, Peterson D, Gaugh M, Zhu T . Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009; 15(2):176-86. PMC: 2747099. DOI: 10.1080/13550280902758973. View

18.

Gomes M, das Neves J, Sarmento B . Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomedicine. 2014; 9:1757-69. PMC: 3984056. DOI: 10.2147/IJN.S45886. View

19.

Schifitto G, Navia B, Yiannoutsos C, Marra C, Chang L, Ernst T . Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007; 21(14):1877-86. DOI: 10.1097/QAD.0b013e32813384e8. View

20.

Medeiros G, Smith F, Trivedi M, Beach S . Depressive Disorders in HIV/AIDS: A Clinically Focused Narrative Review. Harv Rev Psychiatry. 2020; 28(3):146-158. DOI: 10.1097/HRP.0000000000000252. View